Changes of the level of galectin-3, β-2-microglobulin, albuminuria and end glycation products in patients with chronic heart failure and atrial fibrillation under the influence of treatment.
DOI:
https://doi.org/10.26641/2307-0404.2018.2.133695Keywords:
chronic heart failure, atrial fibrillation, galectin-3, β-2-microglobulin, albuminuria, glycation end productsAbstract
The combination of chronic heart failure and atrial fibrillation is considered one of the most prognostically unfavorable alliances among cardiovascular diseases. Now the need for new markers as potential targets for therapeutic intervention is being actively discussed. To date, active study of cardiorenal syndrome continues, which in turn leads to an active search for drugs that reduce nephrologic risk, especially in the category of people with a combined cardiovascular pathology. The aim of the study was to compare the effects of irbesartan and ACE inhibitors on the level of galectin-3, β-2-microglobulin, albuminuria and end glycation products (AGE) in patients with chronic heart failure with atrial fibrillation and impaired renal function. The results of the effect of drugs in patients with chronic heart failure and atrial fibrillation are presented and analyzed. The data indicate the need for more careful attention to this group of patients, namely, the need to diagnose the functional of the kidneys, which is very important for the development of effective interventions aimed at preventing the progression of these diseases.References
But G. [Modern opportunities and prospects for the application of Sartans in clinical practice]. Novosti meditsiny i farmatsii. 2012;7(409). Ukrainian.
Gendlin GE, Reznik EV, Storozhakov GI, Melekhov АV, Uskova OV, Fedorovskaya ТV. [The relationship of atrial fbrillation and renal function in patients with chronic heart failure]. Nefrologiya i dializ. 2010;4:254-61. Russian.
Sychov OS, Kovalenko VM, Dziak GV, Korkushko AV, Bobrov VO, Gryn VK, et al. [Diagnosis and treatment of atrial fibrillation. Recommendations of the working group on violation of cardiac rhythm of Association of Cardiologists of Ukraine]. [Internet]. Available from: http://strazhesko.org.ua/upload/2014/02/20/book_ukr_-10-2011-_preview.pdf. Ukrainian.
Kobalava ZhD. [The efficacy of candesartan in the treatment of heart failure: the results of the CHARM program]. Klinicheskaya farmakologiya i terapiya. 2003;12(5):28-30. Russian.
Kovalenko VM, Lutaj MI, Sirenko JuM. [Cardiovascular diseases. The classification, standards for diagnosis and treatment of cardiac patients]. Kyiv, PP VMB. 2007;128. Ukrainian.
Melnik AA. [The diagnostic value of galectin-3 as a biomarker of heart failure]. Zdorovia Ukrainy. 2015;2(351):32-33. Ukrainian.
Podzolkov VI. [Sartans - the benefits of prolonged use]. Kardiologiya segodnya. 2014;3(9):8-9. Russian.
[Order of HM ofUkrainefrom 03.07.2006 N 436. On approval of the protocols of medical care to patients in specialty Cardiology]. Kyiv; 2006. Ukrainian.
[Order of HM ofUkrainefrom 24.05.2012 N 384. On approval and implementation of medical technology documents on the standardization of medical care for arterial hypertension]. Kyiv; 2012. Ukrainian.
Rebrova OJu. [Statistical analysis of medical data. Application of software package STATISTICA]. Moskva, Mediasphera. 2002;312. Russian.
Voronkov LG, Amosova KM, Bagrij AE, et al. [Recommendations of Association of Cardiologists of Ukraine for the treatment of chronic heart failure in adults (revision 2011)]. Sertseva nedostatnist. 2011;1:101-116. Ukrainian.
Sartans in the practice of a cardiologist: an alternative to an ACEI or an optimal choice? [Internet]. Available from: www.vitamin.com.ua/ru/article/download=81.
Ponikowski P, Voors AA, Anker SD. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur. Heart J. 2016;37(27):2129-200.
Yancy CW, Jessup M, Bozkurt B, Biykem B, Butler J, Casey DE, et al. 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure. JACC. 2017;70(6):776-803.
Khan MA, Fozia A, Neyses L, Mamas MA. Atrial fbrillation in heart failure: The sword of Damocles revisited. World J Cardiol. 2013;5(7):215-27.
JibriniMB. Prevention of atrial fibrillation by way of abrogation of the reninangiotensin system: a systematic review and metaanalysis. Am. J. Ther. 2008;15:36-43.
KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Intern. Suppl. 2013;3(1):5-150.
Healey JS, Baranchuk A, Crystal E, Morillo CA, Garfinkle M, Yusuf S, et al. Prevention of atrial fibrillation with angiotensinconverting enzyme inhibitors and angiotensin receptor blockers: a metaanalysis. J. Am. Coll. Cardiol. 2005;45:1832-9.
Yin Y, Dalal D, Liu Z, Wu J, Liu D, Lan X, et al. Prospective randomized study comparing amiodarone vs. Amiodarone plus losartan vs. amiodarone plus perindopril for the prevention of atrial fibrillation recurrence in patients with lone paroxysmal atrial fibrillation. Eur. Heart. J. 2006;27:1841-6.
Lancefeld TF, Patel SK, Freeman M, Velkoska E, Wai B, et. al. The Receptor for Advanced Glycation End Products (RAGE) Is Associated with Persistent Atrial Fibrillation. PLoS ONE. 2016;11(9):1-13.
Downloads
How to Cite
Issue
Section
License
Copyright (c) 2018 Medicni perspektivi (Medical perspectives)
This work is licensed under a Creative Commons Attribution 4.0 International License.
Submitting manuscript to the journal "Medicni perspektivi" the author(s) agree with transferring copyright from the author(s) to publisher (including photos, figures, tables, etc.) editor, reproducing materials of the manuscript in the journal, Internet, translation into other languages, export and import of the issue with the author’s article, spreading without limitation of their period of validity both on the territory of Ukraine and other countries. This and other mutual duties of the author and all co-authors separately and editorial board are secured by written agreement by special form to use the article, the sample of which is presented on the site.
Author signs a written agreement and sends it to Editorial Board simultaneously with submission of the manuscript.
